After 25+ years of significant cancer research, the North Shore CCOP is applying for its fifth 5-year renewal. In the past 4 years, the North Shore Long Island Jewish Health System's (NSLIJHS) research program screened 2,829 patients and enrolled 1,233 on cancer treatment, prevention and control trials, meeting or exceeding the required annual 50 credits for each grant year. The North Shore CCOP currently offers local access to, and data management support for almost 50 cancer research studies open to accrual through its affiliations with the Cancer and Leukemia Group B, the Radiation Therapy Oncology Group, the National Surgical Adjuvant Breast and Bowel Project, the University of Rochester Cancer Center, the Fox Chase Cancer Center Research Base and the Wake Forest Cancer Center. The goals for the upcoming grant cycle are (1) Increased patient recruitment including improved minority and female enrollment;(2) Increased utilization of community practices and outlying institutions;and (3) Increased CCOP participation from specialists other than medical oncologists, especially in cancer control and prevention trials. The North Shore CCOP has matured into a multidisciplinary research unit. It includes medical, radiation and surgical oncologists from Nassau, Suffolk and Queens Counties in New York. Additional full time support staff including ONS and SOCRA certified nurses, data managers, research coordinators, regulatory staff and others participate at a variety of locations across the catchment area. In 2008, NSLIJHS hospitals accounted for 24% percent of all cancer-related inpatient and ambulatory surgery discharges in New York's Queens, Nassau and Suffolk counties. In 2008, more than 17,650 patients discharged from NSLIJHS hospitals were diagnosed with or treated for cancer. The North Shore CCOP is an integral part of NSLIJHS's cancer services and strives annually to deliver excellent patient care through clinical trials that meet or exceed the National Cancer Institute's clinical trials program requirements.

Public Health Relevance

According to the """"""""Annual Report to the Nation on the Status of Cancer, 1975-2005"""""""", cancer death rates from 2002-2004 decreased at an average rate almost double the annual per year decrease from 1993-2002. This observed decrease in the incidence and death rates from all cancers combined is highly encouraging. However, ongoing research is needed to improve our current methods of prevention, early detection, and treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Feinstein Institute for Medical Research
United States
Zip Code
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Stock, Wendy; Johnson, Jeffrey L; Stone, Richard M et al. (2013) Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer 119:90-8
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Walker, Alison; Mrózek, Krzysztof; Kohlschmidt, Jessica et al. (2013) New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. Genes Chromosomes Cancer 52:385-401
Hickey, Christopher J; Schwind, Sebastian; Radomska, Hanna S et al. (2013) Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 121:159-69
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98

Showing the most recent 10 out of 100 publications